Market Cap: $10.23B
Market Cap: $10.23B

Qiagen NV (Ticker: QGEN) enhances its QIAcuity digital PCR ecosystem with significant advancements recently announced. The new tools expand gene expression capabilities, allow for improved multiplexin…

Qiagen NV (Ticker: QGEN) makes strides in enhancing its QIAcuity digital PCR ecosystem, focusing on advanced gene expression and automation features designed for high-throughput laboratories. The rece…

In the face of ongoing infectious disease challenges, Qiagen NV (Ticker: QGEN) is making significant strides with the recent launch of research-use-only digital PCR assays aimed specifically at the Bu…

Qiagen NV (Ticker: QGEN) launches new digital PCR assays that target the Bundibugyo ebolavirus, a decisive step in strengthening its portfolio of infectious disease research tools. This launch not onl…
Qiagen NV's Analyst Upgrades Signal Recovery Potential Amidst Market Volatility In recent developments, Deutsche Bank upgrades Qiagen NV to a 'buy' rating, a significant shift considering the company’…
Strategic Upgrade Positions Qiagen for Recovery Amid Market Fluctuations Recent analyst activity highlights significant movements for Qiagen NV, particularly following an upgrade from Deutsche Bank th…
Qiagen NV: Pioneering Advances in Diagnostic Testing Amid Industry Developments In the rapidly evolving field of molecular diagnostics, Qiagen NV stands at the forefront of innovation, with a strong e…
Avantor’s Upcoming Earnings Report Signals Strategic Growth in Life Sciences Avantor (NYSE:AVTR) prepares to unveil its quarterly earnings report on October 29, 2025, marking a pivotal moment for the…
Avantor Prepares for Earnings Announcement Amid Strategic Growth Initiatives As Avantor (NYSE: AVTR) approaches its quarterly earnings report scheduled for October 29, 2025, the life sciences and adva…
Revitalizing Diagnostic Solutions: Qiagen's Role in the Life Sciences Landscape In recent developments, Qiagen NV stands at the forefront of transformative changes within the life sciences industry, p…
Strategic Developments in Life Sciences: The Importance of Earnings Reports As Revvity prepares to release its quarterly earnings report on October 27, 2025, the life sciences sector remains focused o…
Qiagen Partners with Foresight Diagnostics to Advance MRD Detection in Hematological Cancers Qiagen NV enters a significant collaboration with Foresight Diagnostics, a leader in diagnostics specializi…
Strategic Partnership Enhances Cancer Diagnostics: Qiagen and Foresight Diagnostics Unite In a significant development in the field of oncology diagnostics, Foresight Diagnostics and Qiagen NV announc…
Qiagen and Foresight Diagnostics Unite to Advance Cancer Detection In a significant development for the field of cancer diagnostics, Foresight Diagnostics has entered into a strategic global partnersh…
Qiagen Sets Date for Q4 2024 Financial Results, Emphasizing Commitment to Molecular Solutions Qiagen N.V., a prominent global provider of Sample to Insight solutions, announces the scheduled release o…
Qiagen N.V. Prepares for Financial Results Announcement Amid Continued Commitment to Innovation Qiagen N.V., a prominent provider of Sample to Insight solutions, gears up to release its fourth quarter…
Qiagen N.V. Initiates Innovative Shareholder Return Strategy Qiagen N.V., the biotechnology company headquartered in Venlo, Netherlands, recently announces an ambitious plan to return up to approximat…
Qiagen's Strategic Shareholder Return Plan Signals Commitment to Value Creation Qiagen N.V., a prominent player in the biotechnology industry, has rolled out an ambitious plan to return up to $300 mil…
Advancements in Gastrointestinal Diagnostics: QIAGEN's Regulatory Milestone QIAGEN NV achieves a significant regulatory milestone with the U.S. Food and Drug Administration’s (FDA) approval of its QIA…
Emerging Opportunities in China's Neurogenomics Market: A Bright Future for Innovation and Growth The neurogenomics market in China is on the cusp of significant expansion, with projections indicating…
Revolutionizing Biological Data Interpretation: QIAGEN's IPA Interpret Launch QIAGEN NV has recently unveiled a significant advancement in the realm of biomedical research with the introduction of the…
QIAGEN Expands QIAstat-Dx Operations in Barcelona: A Strategic Move for Enhanced Diagnostics QIAGEN NV announces a significant expansion of its QIAstat-Dx operations with plans to relocate to a new fa…
QIAGEN Expands QIAstat-Dx Operations to Barcelona for Enhanced Diagnostic Solutions QIAGEN NV announces its strategic decision to relocate its QIAstat-Dx operations to a new facility in Esplugues de L…
Growth Prospects in the In Vitro Diagnostics Market: A Crucial Insight for Qiagen NV The global in vitro diagnostics (IVD) market is on an upward trajectory, projected to reach USD 108 billion by 2024…
Legal Tensions in Biotech: Zymo Research Challenges Qiagen's Practices In a significant legal development, Zymo Research Corporation, headquartered in Irvine, California, initiates a lawsuit against Q…
Legal Dispute Between Zymo Research and Qiagen Highlights Industry Tensions Zymo Research Corporation, a prominent player in the life sciences sector, initiates legal proceedings against Qiagen GmbH,…